MX2009013019A - Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica. - Google Patents

Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.

Info

Publication number
MX2009013019A
MX2009013019A MX2009013019A MX2009013019A MX2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A
Authority
MX
Mexico
Prior art keywords
suspensions
drug release
resin systems
ionic resin
modifying drug
Prior art date
Application number
MX2009013019A
Other languages
English (en)
Inventor
Mark Tengler
Russell Lee Mcmahen
Yashwant Vishnupant Pathak
Original Assignee
Neos Therapeutics Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neos Therapeutics Lp filed Critical Neos Therapeutics Lp
Publication of MX2009013019A publication Critical patent/MX2009013019A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin

Abstract

La presente invenci?n incluye composiciones y m?todos para suministrar una o m?s unidades de dosificaci?n unitaria mediante la modificaci?n del perfil de liberaci?n de un complejo de resina de f?rmaco opcionalmente recubierto, suspendido en una soluci?n de sal i?nica, en donde el complejo de resina de f?rmaco opcionalmente recubierto incluye uno o m?s agentes activos cargados en una o m?s part?culas de resina de intercambio de iones y en donde la liberaci?n de uno o m?s agentes activos es modulada por una o m?s sales i?nicas en soluci?n.
MX2009013019A 2007-05-30 2008-05-30 Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica. MX2009013019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94095607P 2007-05-30 2007-05-30
PCT/US2008/065408 WO2008151071A1 (en) 2007-05-30 2008-05-30 Modifying drug release in suspensions of ionic resin systems

Publications (1)

Publication Number Publication Date
MX2009013019A true MX2009013019A (es) 2010-04-01

Family

ID=40094143

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013019A MX2009013019A (es) 2007-05-30 2008-05-30 Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.

Country Status (6)

Country Link
US (1) US8313770B2 (es)
EP (1) EP2164631A4 (es)
JP (1) JP2010529040A (es)
CA (1) CA2689101C (es)
MX (1) MX2009013019A (es)
WO (1) WO2008151071A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
CN102123938A (zh) 2007-09-06 2011-07-13 可口可乐公司 用于提供混合饮料分配器中的份量控制编程的系统和方法
CN101821193B (zh) 2007-09-06 2015-04-01 可口可乐公司 监测和控制多种产品形成成分的分配的系统和方法
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
MX2012006320A (es) 2009-12-02 2013-01-18 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
US8470375B1 (en) 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
US20130230587A1 (en) * 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US9339478B2 (en) * 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
US8287903B2 (en) * 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2508174A1 (en) * 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US20130004586A1 (en) * 2011-06-24 2013-01-03 Vachon David J Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same
WO2013003622A1 (en) 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
US20140122120A1 (en) * 2012-10-30 2014-05-01 Pacesetter, Inc. Systems and methods for providing photo-based patient verification for use with implantable medical device programmers
WO2014132163A1 (en) * 2013-02-28 2014-09-04 Pfizer Inc. Enhanced stability of novel liquid compositions
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US20170128379A1 (en) * 2014-06-30 2017-05-11 Rubicon Research Private Limited Modified release pharmaceutical preparations
CN107074672A (zh) * 2014-10-01 2017-08-18 农作物增强公司 用于农业应用的农用化学品树脂酸盐
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CA3022933A1 (en) * 2016-05-03 2017-11-09 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US11690840B2 (en) 2017-10-09 2023-07-04 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
WO2019094292A1 (en) * 2017-11-09 2019-05-16 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone of analogs thereof
US11337919B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
WO2019126215A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK79841C (da) * 1952-08-04 1955-09-12 Behringwerke Ag Fremgangsmåde til fremstilling af stabile γ-globulinpræparater.
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
AU565487B2 (en) * 1983-09-16 1987-09-17 Fisons Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
US4762709A (en) * 1983-09-16 1988-08-09 Pennwalt Corporation Liquid prolonged release pharmaceutical formulations containing ionic constituents
US4692462A (en) * 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
JP4808405B2 (ja) * 2002-11-26 2011-11-02 ホ−レンベック ギャリ− ア−ル 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
JP2008546835A (ja) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations

Also Published As

Publication number Publication date
US20090011027A1 (en) 2009-01-08
EP2164631A4 (en) 2013-08-21
EP2164631A1 (en) 2010-03-24
US8313770B2 (en) 2012-11-20
CA2689101C (en) 2013-01-22
WO2008151071A1 (en) 2008-12-11
CA2689101A1 (en) 2008-12-11
JP2010529040A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
MX2009013019A (es) Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.
CY1122732T1 (el) Συνθεσεις για αναπνευστικη χορηγηση δραστικων παραγοντων και συναφεις μεθοδοι και συστηματα
MX2014000141A (es) Agentes de enlace a receptor de canabinoide, composiciones y metodos.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
UA122868C2 (uk) Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування
PH12016500372A1 (en) Pharmaceutical composition containing pyrimidine compound as active ingredient
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
HK1153636A1 (en) Ophthalmic devices for the controlled release of active agents
MX2015015589A (es) Composiciones y metodos para el suministro de agentes activos hidrófobos.
MX2013008146A (es) Mejoras en tecnologia de revestimiento.
MY161236A (en) (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
SG182629A1 (en) Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
MX341642B (es) Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
MX2012001693A (es) Formulaciones estables no corrosivas para inhaladores presurizados de dosis medida.
EA200800464A1 (ru) Фармацевтическая композиция, содержащая периндоприл или его соли
MX2009003815A (es) Formulaciones farmaceuticas.
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
EP2568990A4 (en) METHOD OF PRODUCING PLEURODESIS
MX357799B (es) Nuevo sistema de liberación de proteínas hidrofóbicas.
GB201004677D0 (en) New salt
CL2013000174A1 (es) Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis.
WO2022146367A3 (en) Nanocone clusters suitable for use as histotripsy agent
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии

Legal Events

Date Code Title Description
FA Abandonment or withdrawal